Member Info for crumbs

It could be Dr Alan Lewis who is manning the San Diego office

I think you will find most of us say this is a high risk/reward share... well apart from one :) .. but maybe Evans is quite revealing and insightful comments over on the darkside will temper that view too.... It was though IMHO a much more riskier share during Evans time at the company not due to anything to do with him just we were a company with very little clinical data back then and moditope in its infancy and no glycan MaBs... I say we are a less risky risk/reward share now than at any other time in scancells history but indeed.... you say it the 'ugly sister' never the bride always the bridesmaid it is this that keeps the risk factor here... until we seal that first commercial money in the bank deal this remains the case... however if you think and just a read through the most recent presentation PDF makes me go wow (I think even most of us could flog those wares at any Bio event!)... that scancell have something valuable then it is worth the risk as the rewards could be very high indeed... still that one piece of the jigsaw does need to fall into place and I've given up on when it will I just feel it will....each to there own and indeed everyone should DYOR .... This sector is only getting hotter.

Nice to see glycan MABs make much more of an appearance... BiONtech collaboration still on and what a portfolio of IP scancell has! Got to be very deal/s attractive now.

I suppose it is like saying you do not think there should be a Q&A at AGM...I'm sure we all agree that is preposterous we should be able to communicate with the BOD we have invested in .... to what level is something else but like I say as far as I know scancell are always professional in their relationship to pi's and no doubt ii's too... I know Glencross of calculus has a weekly call with CH as indeed they do with all their investments... maybe Woodford should have done that instead of prancing around on race horses.

I doubt the amount of time spent on emails interferes with getting the likes of vulpes and other ii to invest in scancell :) I much prefer a BOD that communicates as best it can with ALL shareholders. after all, when those OO's occur it is current pi's they want to invest more as much as ii.. of course, there will be times when certain emails need to be given a generic reply ... but I have always been satisfied with the few emails I've been sent replies, of course, nothing 'insider' is given out but you can learn certain things, for instance, I learnt that sarcomas were replaced by head and neck due to work done with project blueprint etc... things you do not learn from RNS's but are of great interest to us pi's

Indeed more we like to hear the Q&A's and after-show 'chats' :) the rest we usually know already... if it is sold out already it must be well attended though not heard anyone here saying they will attend :(

The website needs updating don't even think Diggle has appeared on the BOD on there yet... I'm sure the cost of recording and putting up a vid would be only a few quids these days... Anyways hopefully we get some feedback

the early birds are chirpy today :).... So an update on both ImmunoBody and moditope at this investors event...really hope we do get some feedback but yeah possibility of an RNS this AM

Well like I say at least one was close... we do not know which but like this Vulpes buy in they were on the scene for years before committing... it just takes that one moment of now is the time and that is it everything changes... I am sure there are some very exciting names who are looking closely and have been for years at what scancell are up to... yeah it is frustrating and when others get the deals and we do not and often on what is lesser looking techs it does raise questions.. but we have seen... proff Sahin and Mellman are interested and it is them and people like them that will one day go 'we have to get in now'... anyways who knows maybe a bit more will be revealed at this coming investors event... shame no one here is going?... only we have done well with attendees to such events in the past and recordings etc... so hopefully someone is going and can at least give some feedback.

Back to the dinghy :)
Seems there are a lot of big money deals being done for products that though offer potential have not proven it yet... anyways a nice sector to be in if you can indeed pull off one of those deals!

Fact is your right no partner no buyer... we were told came very close to a deal though but I agree coming close to and closing a deal may as well be miles apart for what good that does us as shareholders... but left on the shelf as product is wrong as you can see it is about to go into combo trial and also attracted the attention of the best clinician in the US and associates and their top clinics... so to say left on a shelf is a bit harsh especially as there are people most likely alive today thanks to that vaccine....
...also scancell are not a one-trick one product one platform company with MaBs we can now say we have 3 platforms with multiple potential product deals.. the first one is going to be vital... I'm willing to wait it out :)

If I remember he did write an alright article about SCIB1 but did not seem that excited by the science behind ImmunoBody though did not seem to bother going into it in depth ... basically, he has his own pet favourite scientific approaches( like so many of them do).... He was also on a panel I think with Lindy a couple of years back and knows about moditope, RG once replied to one of his tweets promoting moditope but he never replied back... He is one that will be needing (positive) data to wake him up

I think CAR T's and CI's are already being trialled in combo....

Well, we get told here often... the market never lies! Usually only when sp is sinking though :)

Earlier this year, BioNTech had hired Bank of America and JP Morgan to prepare for a listing on the NASDAQ, which could have raised as much as $800 million at a valuation of around $4 billion, according to Reuters. While the company is reportedly still weighing various financing options, it isn't short on cash considering this latest transaction plus its hefty $270 million Series A last year.

As if BioNTech's Series B wasn't enough for Europe, ADC Therapeutics announced on the same day that it has secured an additional $103 million for its Series E, bringing the total amount raised for the round to a whopping $303 million. The Swiss startup develops therapies to treat hematological cancers and solid tumors and, like BioNTech, plans to use the funds for clinical trials.

Both transactions are indicative of the direction in which the European biotech industry is heading. Companies in the sector raised a record €1.3 billion in 2018, per the PitchBook Platform, having recovered from a brief lull which saw the amount of funding received dip in the two preceding years. The question is, what is fueling this uptick in activity? Increasing participation in European rounds from US investors may be one potential reason. Firms such as the Bay Area-based Redmile Group—whose portfolio includes both BioNTech and ADC—are expanding their horizons and increasingly looking outside of their borders for investment opportunities.

VC interest in the industry is also likely inspired by the big payoffs that investors can potentially expect when it comes time to exit. Deals such as Lundbeck acquiring the Netherlands-based Prexton Therapeutics' for up to €905 million and Novo Nordisk buying British business Ziylo for some $800 million have shown that the European biotech industry is a good space for those hunting for alpha.

Quick go back out and in again another 10 times :)

I'm not sure it is deliberate and for now, will go with my 'bureaucracy' take... Ichor is a US company after all... SCIB1 has US orphan status and uses US licensed tech it has the greatest US clinicians and clinics wanting to run the trial... I just cannot see how it can be because we are a tiny UK biotech... though in a world of Trump who knows!... I know the FDA commisioner left recently and has since joined Pfizer.... I do totally feel your frustration with the situation though... it verges on the criminal to my mind.... wonder what happens if there is no US arm yet UK arm is producing very positive results!... I am at least relived scancell acted fast in including I belive lastminute due to FDA the UK arm.. that is a company reacting.. as for UK having no probs with trial well why should they? The last one was a great success with no drug related issues and the device is already in clinical use.... In many ways ... as now scancell are looking beyond electroporation with nano delivery this trial in US is of more value to Ichor... as surely they at some point need their new device to be approved for trial by the FDA... the old one certainly has been with even the US army using it!!!!..... I think we will get the US arm started this year.... glad we are doing modi1 UK only though... The bigger issue for me is Lindys immuno approach has had clinical success since the late 90s... why has she never been pushed forwards and backed for all these years??? to my mind that is also outrageous but hey... we may get the last word there and it may be as soon as next year.

Certainly, their constant expansion is amazing and seemingly unstoppable!... I doubt there is a biotech company out there with even half the ambition of BioNTech and yet really clinically they are not that far ahead of scancell... It will be interesting to hear if the planned IPO is still on...reading some articles about today's fundraiser it seems they are keen to get into the Chinese market too...

Well that is interesting.... and unexpected really seeing as they were keen on the US IPO but who knows maybe that is still in their plans.... What I do know is after their last fundraising in 2018 they pretty soon announced the research collaboration with scancell.

No, I only saw clips of that one... what we can say for sure and that was not the case when we first got in here... Immunotherapy has gone totally mainstream now and is only going to advance until one day there are enough keys to unlock all cancers defences ...also though far far from an expert I actually am quite clued on the mechanisms now which I was not at the begining I fully understood to science behind last nights CAR T though of course the actual practicalities of turning concept science into a usable product are where great skills are needed... hence modi1 becoming clinically ready is massive and was no small task as I have no doubt is the TCR work going on with BioNtech this really is edge of the cutting edge stuff and then requires trials and those willing to participate in those trials... as was said in last nights doc... in many ways it is those who fail in the trials who produce the most valuable data as lessons are learnt and products improved and clinical regimes can then be altered to benefit the next patients.... The battle goes on as you well know mate....hope we get news of our first SCIB1 combo patients dosed soon and that bloody FDA pulls its finger out as it is not like we do not have the techs ready and waiting and for sure the patients in need are!

TF I believe there are now commercial products from both Kite and Junos pipelines... the cost of CAR T is massive something else you could appreciate from the documentary the amount of care patients on those trials require is massive without even factoring in the cost of manufacturing etc.... however if treatments do work in a great enough % it does look like the costs will be worth it...and indeed covered